You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 166 No. 5, March 13, 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (2)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Health Policy
 •Substance Abuse/ Alcoholism
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Racial Disparities in Access After Regulatory Surveillance of Benzodiazepines

Sallie-Anne Pearson, PhD; Stephen Soumerai, ScD; Connie Mah, MS; Fang Zhang, PhD; Linda Simoni-Wastila, PhD; Carl Salzman, MD; Leon E. Cosler, PhD, RPh; Thomas Fanning, PhD; Peter Gallagher, PhD; Dennis Ross-Degnan, ScD

Arch Intern Med. 2006;166:572-579.

Background  We examined the effects of a prescription-monitoring program on benzodiazepine access among Medicaid enrollees living in neighborhoods of different racial composition.

Methods  We used interrupted time series and logistic regression to analyze data from noninstitutionalized persons aged 18 years or older (N = 124 867) enrolled continuously in New York Medicaid 12 months before and 24 months and 7 years after initiation of the program. We used census data to identify the racial composition of the neighborhoods. Outcome measures were nonproblematic use (short term, within dosing guidelines), potentially problematic use (>120 days' use or more than twice the recommended dose), and pharmacy hopping (filling prescriptions for the same benzodiazepine in different pharmacies within 7 days).

Results  There was a sudden, sustained reduction in benzodiazepine use in all the neighborhoods after the program's introduction. Despite the lowest rates of baseline use, enrollees in predominantly (≥75%) black neighborhoods experienced the highest rates of discontinuation after introduction of the program. This difference remained 7 years after policy initiation. Compared with white participants, black participants were more likely to discontinue nonproblematic (odds ratio, 1.78; 95% confidence interval, 1.47-2.17) and potentially problematic (odds ratio, 1.77; 95% confidence interval, 1.45-2.17) benzodiazepine use, after adjusting for sex, eligibility status, neighborhood poverty, and baseline use. The program almost completely eliminated pharmacy hopping in all racial groups, although less among white participants (82.6%) vs black participants (88.7%).

Conclusions  A systematic benzodiazepine prescription-monitoring program reduced inappropriate prescribing, with a stronger effect in predominantly black neighborhoods despite lower baseline use. The policy may have resulted in an unintended decrease in nonproblematic use that disproportionately affects black populations.


Author Affiliations: Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Mass (Drs Pearson, Soumerai, Zhang, and Ross-Degnan and Mss Mah); School of Population Health and Community Medicine, University of New South Wales, Sydney, Australia (Dr Pearson); Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore (Dr Simoni-Wastila); Department of Psychiatry, Harvard Medical School and Massachusetts Mental Health Center, Boston (Dr Salzman); Department of Humanities and Social Sciences, Albany College of Pharmacy, Albany, NY (Dr Cosler); and Knowledge and Information Management Group, Office of Medicaid Management, New York State Department of Health, Albany (Drs Fanning and Gallagher).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Benzodiazepine Use and Expenditures for Medicare Beneficiaries and the Implications of Medicare Part D Exclusions
Yang et al.
Psychiatr. Serv. 2008;59:384-391.
ABSTRACT | FULL TEXT  

Effect of New York State Regulatory Action on Benzodiazepine Prescribing and Hip Fracture Rates
Wagner et al.
ANN INTERN MED 2007;146:96-103.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.